Gastroesophageal reflux disease (GERD) is a chronic condition in which gastric contents flow backward through a dysfunctional lower esophageal sphincter (LES) and damage the esophageal mucosa. It affects roughly 20% of adults in the US, making it one of the most common GI diagnoses in both outpatient and inpatient nursing. The classic presentation – heartburn and regurgitation – is only part of the picture. Many patients present with atypical symptoms: hoarseness, chronic cough, or dental erosion, a syndrome called laryngopharyngeal reflux (LPR) that most nursing resources omit entirely. GERD also sits on a progression continuum that can end in esophageal adenocarcinoma through Barrett’s esophagus.
This reference covers the full scope: LES dysfunction mechanics, erosive vs. non-erosive disease, typical vs. atypical presentations, diagnostics including ambulatory pH monitoring, the Los Angeles classification of erosive esophagitis, Barrett’s esophagus surveillance intervals, priority nursing interventions with rationale, PPI pharmacology and its critical interaction with clopidogrel, and post-surgical nursing care for Nissen fundoplication and the LINX device. For peptic ulcer disease driven by H. pylori, see the peptic ulcer disease nursing reference. For GI bleeding from esophageal erosions or varices, see the GI bleed nursing reference.
| Quick reference | Details |
|---|---|
| Definition | Chronic retrograde flow of gastric contents through a defective LES causing mucosal damage |
| Primary mechanism | Transient LES relaxations (tLESR) or persistently low resting LES pressure |
| Classic symptoms | Pyrosis (heartburn), regurgitation, water brash |
| Atypical/LPR symptoms | Hoarseness, globus, chronic cough, dental erosion, laryngitis |
| Alarm symptoms | Dysphagia, odynophagia, unintentional weight loss, GI bleeding → immediate EGD |
| First diagnostic step | Empiric PPI trial – 8 weeks, once daily, before a meal (ACG 2022) |
| Gold-standard diagnostic | 24-hour ambulatory pH monitoring |
| First-line treatment | PPI 30–60 min before first meal; lifestyle modification |
| Key complication | Barrett’s esophagus → esophageal adenocarcinoma |
| Nursing priority | Symptom control, medication adherence, HOB elevation, aspiration prevention |
Pathophysiology
The LES is a 3–4 cm zone of tonically contracted smooth muscle at the gastroesophageal junction. Resting LES pressure normally sits between 10–45 mmHg – enough to resist gastric pressure. GERD results when this barrier fails by one of three mechanisms:
Transient LES relaxations (tLESR): The dominant mechanism in most GERD patients. The LES briefly relaxes independent of swallowing, triggered by gastric distension and mediated through the vagus nerve. These episodes are normal in small numbers (physiologic reflux), but GERD patients have a much higher frequency of tLESRs, particularly after large meals.
Hypotensive LES: A resting LES pressure below 10 mmHg allows continuous retrograde flow. This is characteristic of severe erosive disease and often associated with hiatal hernia. When the LES migrates above the diaphragmatic hiatus in a hiatal hernia, it loses the mechanical support of diaphragmatic contraction and crural compression, further reducing the antireflux barrier.
Impaired esophageal clearance: Under normal conditions, peristaltic contractions sweep refluxed acid back into the stomach within 1–2 swallows, and bicarbonate-rich saliva neutralizes residual acid. In GERD patients, ineffective esophageal motility and reduced salivary output (worsened by mouth breathing, smoking, and sleep) prolong acid contact time, amplifying mucosal injury.
Erosive vs. non-erosive reflux disease (NERD): Roughly 50–70% of GERD patients have NERD – symptoms and abnormal pH studies without visible mucosal breaks on endoscopy. NERD patients report equivalent or worse symptom burden than erosive patients, but their mucosa is intact. This distinction matters clinically: NERD patients respond less predictably to PPIs, and a normal endoscopy does not rule out GERD.
Clinical presentation
Typical symptoms
- Pyrosis (heartburn): Retrosternal burning that rises toward the throat, worsened by large meals, lying supine, bending forward, and NSAIDs or alcohol. Classically improves with antacids.
- Regurgitation: Effortless return of sour or bitter gastric contents to the mouth or throat, without nausea or retching. This distinguishes GERD regurgitation from vomiting.
- Water brash: Sudden flooding of the mouth with clear, slightly salty fluid from reflex salivary hypersecretion. Often confused with regurgitation.
Atypical and extraesophageal symptoms (LPR)
Laryngopharyngeal reflux occurs when gastric contents bypass the upper esophageal sphincter and reach the larynx and pharynx. LPR and GERD are now considered distinct – though overlapping – conditions. Critically, nearly 100% of LPR patients report hoarseness, whereas virtually no classic GERD patients do. LPR typically occurs during daytime upright activity, while classic GERD worsens at night in the recumbent position.
| Symptom type | Classic GERD | LPR (silent reflux) |
|---|---|---|
| Pyrosis (heartburn) | Present in most | Absent in up to 40% |
| Regurgitation | Common | Less prominent |
| Hoarseness | Rare | Cardinal symptom |
| Globus (lump in throat) | Uncommon | Common |
| Chronic throat clearing | Uncommon | Very common |
| Chronic cough | Occasional | Prominent |
| Dental erosion | Rare | Can occur with chronic exposure |
| Symptom timing | Nocturnal/recumbent | Daytime/upright |
| LES dysfunction | Lower LES dominant | Upper LES dominant |
The Reflux Symptom Index (RSI), validated by Belafsky and colleagues in 2002, is a 9-item patient-reported questionnaire scored 0–5 per item for a maximum of 45. A score above 10 indicates a high probability of reflux pathology. Nursing assessment should screen for hoarseness, globus, and chronic cough in any patient with unexplained upper respiratory symptoms.
Diagnostics
Empiric PPI trial: The standard first step for uncomplicated, typical GERD symptoms. The 2022 ACG guideline recommends an 8-week trial of once-daily PPI taken before a meal; symptom resolution supports a clinical diagnosis, and the guideline then recommends attempting to discontinue the PPI. EGD is not required unless alarm symptoms are present.
Alarm symptoms requiring prompt EGD: Dysphagia, odynophagia, unintentional weight loss, hematemesis, melena, vomiting, and iron-deficiency anemia. These features may indicate esophageal stricture, ulcer, or malignancy. ACG also recommends endoscopy for patients carrying multiple Barrett’s esophagus risk factors (chronic weekly reflux for 5+ years plus male sex, age over 50, smoking, central obesity, or a family history of Barrett’s or esophageal adenocarcinoma).
Upper endoscopy (EGD): Visualizes mucosal breaks, Barrett’s changes, strictures, and mass lesions. Required for alarm symptoms and failed PPI trial, and used for surveillance in confirmed Barrett’s esophagus at the intervals listed below. Note that endoscopic findings are not all equally diagnostic: ACG states LA grade A erosive esophagitis is not sufficient for a definitive GERD diagnosis because it cannot be reliably distinguished from normal, grade B is diagnostic when typical symptoms and PPI response are also present, and grade C is virtually always diagnostic.
Ambulatory pH monitoring: The gold standard for confirming pathologic acid exposure. Two methods:
- 24-hour pH catheter: A thin probe is placed transnasally and positioned 5 cm above the LES. It records pH continuously over 24 hours while the patient maintains a symptom diary. Useful for correlating symptoms with acid episodes.
- Bravo wireless pH capsule: A small capsule is clipped to the esophageal wall during endoscopy and transmits pH data wirelessly for 48–96 hours. Better tolerated than catheter; patients can eat and sleep normally. The capsule detaches spontaneously within 7–10 days.
Esophageal manometry: Measures LES resting pressure and peristaltic contraction patterns. Required before anti-reflux surgery to rule out achalasia or major motility disorders (a dysfunctional esophagus cannot tolerate a wrap).
Complications
Erosive esophagitis: Los Angeles classification
| Grade | Endoscopic finding | Diagnostic and treatment significance (ACG 2022) |
|---|---|---|
| A | One or more mucosal breaks ≤5 mm, not crossing between folds | Not sufficient for a definitive GERD diagnosis – cannot be reliably distinguished from normal |
| B | One or more mucosal breaks >5 mm, not crossing between folds | Diagnostic of GERD when typical symptoms and PPI response are also present |
| C | Mucosal breaks crossing between ≥2 folds, <75% of esophageal circumference | Virtually always diagnostic of GERD; indefinite maintenance PPI or antireflux surgery recommended |
| D | Mucosal breaks involving ≥75% of esophageal circumference | Severe GERD in outpatients; indefinite maintenance PPI or antireflux surgery recommended |
Grades C and D carry the highest relapse risk: nearly 100% of patients with LA grade C esophagitis relapse within 6 months of stopping PPIs, which is why ACG recommends they stay on long-term therapy to maintain healing rather than attempting discontinuation.
Barrett’s esophagus
Chronic acid exposure drives metaplasia: the normal stratified squamous epithelium of the distal esophagus is replaced by intestinal-type columnar epithelium containing goblet cells. Barrett’s esophagus is the single most important risk factor for esophageal adenocarcinoma (EAC). Per the 2022 ACG guideline, diagnosis requires at least 1 cm of columnar-lined esophagus with biopsy confirming intestinal metaplasia, and a dysplasia diagnosis must be confirmed by a second pathologist with expertise in esophageal histopathology.
Barrett’s is common in GERD but not universal. The prevalence of Barrett’s among patients with GERD symptoms alone is roughly 2.3%, rising to about 12.2% in those with GERD plus one additional risk factor, and each further risk factor adds approximately 1.2 percentage points.
Progression risk rises steeply with dysplasia grade. Annual rates reported in the 2022 ACG guideline:
- Nondysplastic BE (NDBE): approximately 0.05–0.2% per year to EAC. Segment length matters – annual progression to EAC was 0.07% for segments under 3 cm versus 0.25% for segments 3 cm or longer
- Low-grade dysplasia (LGD): approximately 0.7% per year overall. In a Dutch cohort where expert pathologists confirmed the LGD diagnosis, confirmed LGD progressed to HGD or cancer at 9.1% per patient-year, while cases downstaged on expert review progressed at 0.6–0.9% per patient-year
- High-grade dysplasia (HGD): endoscopic eradication therapy recommended rather than surveillance
That LGD spread is the clinically important number: the difference between 0.7% and 9.1% is driven almost entirely by whether an expert pathologist confirms the diagnosis, which is why second-pathologist confirmation changes management rather than merely documenting it.
Surveillance intervals (2022 ACG guideline):
- NDBE <3 cm: EGD every 5 years
- NDBE ≥3 cm: EGD every 3 years
- Indefinite for dysplasia (confirmed by a second pathologist): repeat EGD within 6 months after increasing to twice-daily PPI; if still indefinite, EGD annually
- LGD (confirmed by a second pathologist, opting for surveillance): EGD at 6 months, then 12 months, then annually
- HGD: endoscopic eradication therapy (radiofrequency ablation preferred over surveillance)
Radiofrequency ablation (RFA): For LGD and HGD, RFA is the standard endoscopic eradication therapy. In the SURF trial, 1.5% of treated LGD patients progressed to HGD or EAC at 3 years versus 26.5% in the surveillance group – a difference large enough that the trial was stopped early.
Post-RFA surveillance after complete eradication of intestinal metaplasia is tailored to the worst pretreatment histology, not applied as one schedule:
- LGD before ablation: EGD at 1 year, 3 years, then every 2 years
- HGD before ablation: EGD at 3 months, 6 months, 12 months, then annually
- Intramucosal carcinoma before ablation: EGD at 3 months, 6 months, 12 months, then annually
ACG does not recommend stopping surveillance after eradication unless the patient’s overall medical status dictates it.
Other complications
- Esophageal stricture: Repeated cycles of inflammation and healing deposit collagen, narrowing the lumen. Presents as progressive solid-food dysphagia. Treated with endoscopic dilation.
- Aspiration pneumonia: Nocturnal reflux and microaspiration can cause recurrent pneumonia, especially in patients with impaired gag reflex or neurologic compromise.
Nursing interventions
| Intervention | Rationale | Timing/frequency |
|---|---|---|
| Elevate HOB 30–45° | Gravity prevents retrograde acid flow; reduces nocturnal aspiration risk | Continuous; use foam wedge or adjustable bed frame – not extra pillows alone |
| Avoid supine position 2–3 hours after meals | Postprandial period has highest tLESR frequency; supine positioning eliminates gravity barrier | After each meal; educate patient on meal-to-bed timing |
| Encourage small, frequent meals (4–6/day) vs. large meals | Large meals increase gastric distension, the primary trigger for tLESR episodes | At every meal; reinforce during patient teaching |
| Counsel on trigger foods | Fatty foods, chocolate, caffeine, alcohol, peppermint, and citrus reduce LES pressure or increase acid secretion | During patient education; provide written list |
| Weight reduction counseling | 5–10% body weight reduction significantly decreases GERD symptom frequency and severity; abdominal adiposity increases intragastric pressure | Each encounter; refer to dietitian if BMI >30 |
| Smoking cessation support | Nicotine relaxes LES and reduces salivary bicarbonate production, impairing acid clearance | Each encounter; refer to cessation program |
| Administer PPI 30–60 min before first meal | PPIs are prodrugs activated only by acid secretion during active pumping; timing with meals ensures maximum parietal cell activation | Once or twice daily per order; document timing |
| Avoid crushing or splitting PPI capsules | Enteric coating protects the prodrug from premature acid activation in the stomach | Each administration |
| H. pylori screen before long-term PPI initiation | PPIs suppress H. pylori density and urease activity, reducing test sensitivity; if H. pylori is present and untreated, PPI therapy alone risks masking infection | Order/confirm before starting therapy; urea breath test requires 2-week PPI hold |
| Monitor for PPI-clopidogrel interaction | Omeprazole and esomeprazole competitively inhibit CYP2C19, the same enzyme required to activate clopidogrel to its active antiplatelet form; this reduces clopidogrel efficacy | On admission review for patients on dual antiplatelet therapy; prefer lansoprazole, pantoprazole, or rabeprazole |
| Monitor for PPI adverse effects | Long-term use: hypomagnesemia, C. difficile risk, vitamin B12/iron malabsorption, rebound hypersecretion on discontinuation | Electrolytes (Mg²⁺) per protocol; B12 annually on long-term PPI |
| Post-fundoplication: monitor for dysphagia | Short-term dysphagia is expected from perioperative edema and wrap tension; dysphagia persisting >3 months may indicate wrap slippage and requires barium swallow | Every meal interaction in immediate post-op; reassess at follow-up visits |
| Post-fundoplication: gas-bloat syndrome education | The wrap prevents belching and vomiting; patients accumulate gas; self-limiting in 2–4 weeks but distressing without preparation | Preoperatively and immediately post-op; advise low-gas diet |
| LINX device: MRI restrictions | LINX is a magnetic device and is MR Conditional only. Current devices are labeled for MRI systems up to 1.5 Tesla; scanning outside labeled conditions can injure the patient and demagnetize the implant. Older devices carry lower limits, so verify the specific implant record | Reinforce at every care encounter; document device model in the medical record and device reconciliation |
| Teach-back on lifestyle modifications | Confirms patient understanding; lifestyle change is the only durable non-pharmacologic control | Before discharge and at each follow-up |
Post-operative diet progression (Nissen fundoplication)
Standard post-op diet follows a phased approach to allow the surgical wrap to heal:
- Days 1–7: Clear liquids and full liquids; no carbonated beverages
- Weeks 2–4: Soft, moist foods (scrambled eggs, yogurt, bananas); chew thoroughly; no large bites
- Week 4–6: Gradual reintroduction of solid foods; avoid tough meats and bread initially
- Long-term: Avoid foods that cause excess gas (carbonated drinks, beans, broccoli, cabbage); eat slowly; avoid drinking large volumes with meals
Medications
| Medication class | Drug names | Mechanism | Key nursing considerations |
|---|---|---|---|
| PPI (first-line) | Omeprazole, pantoprazole, lansoprazole, esomeprazole, rabeprazole | Irreversibly blocks H⁺/K⁺-ATPase on parietal cells | Administer 30–60 min before first meal; avoid omeprazole/esomeprazole with clopidogrel; screen for H. pylori before starting; monitor Mg²⁺ on long-term use |
| H2 receptor antagonist | Famotidine | Blocks H2 receptors, reducing histamine-stimulated acid secretion | Less potent than PPIs; tachyphylaxis (tolerance) develops with scheduled use within days; better for PRN symptom relief or nighttime dosing adjunct |
| Antacid | Calcium carbonate, magnesium hydroxide/aluminum hydroxide | Directly neutralizes gastric acid | Fastest onset (minutes); calcium carbonate can cause rebound acid secretion with excessive use; separate antacids from other oral medications by ≥2 hours (binds drugs) |
| Alginate-based preparation | Gaviscon (sodium alginate + sodium bicarbonate) | Forms viscous raft on top of gastric contents, providing mechanical barrier at GEJ | Particularly effective for postprandial symptoms; take after meals and at bedtime |
| Prokinetic | Metoclopramide | D2 antagonist; increases LES tone, accelerates gastric emptying | Reserve for gastroparesis-complicated GERD; FDA black box warning for tardive dyskinesia with long-term use (>12 weeks); avoid in Parkinson’s disease |
| Sucralfate | Sucralfate | Coats and protects esophageal/gastric mucosa | Take on empty stomach; separate from other medications. ACG 2022 recommends against sucralfate for GERD except during pregnancy; its main role is in PUD |
Barrett’s esophagus nursing considerations
Patients with confirmed Barrett’s esophagus require structured surveillance because most will never develop cancer – but those who do progress through a defined dysplasia sequence. Nursing education focuses on three points: why surveillance matters even when they feel well, what to expect from endoscopic procedures (including RFA), and the lifestyle modifications that may slow progression (continued PPI use even in asymptomatic patients, weight management, smoking cessation).
RFA patients require preoperative education about the procedure (a balloon or focal catheter delivers radiofrequency energy to ablate abnormal mucosa), post-procedure expectations (chest discomfort, odynophagia for 5–10 days, liquid diet), and the importance of completing the full surveillance schedule. Complete eradication of intestinal metaplasia (CEIM) is the target – but residual islands of metaplasia can persist and require repeat treatment.
Dysplasia grading must be confirmed by two expert pathologists due to significant interobserver variability. Nursing documentation should reflect any upgrades or downgrades in dysplasia grade at each surveillance interval, as this changes the management algorithm.
NCLEX tips
-
PPI timing is a classic NCLEX question: PPIs should be administered 30–60 minutes before the first meal of the day, not at bedtime, not with food. If a patient is on twice-daily dosing, the second dose goes 30–60 minutes before dinner.
-
Alarm symptoms require escalation: Dysphagia, unexplained weight loss, GI bleeding, or anemia in a GERD patient always warrant upper endoscopy. Reassigning these patients to continued PPI therapy without further workup is the wrong answer.
-
The correct HOB elevation uses a foam wedge, not extra pillows: Stacking pillows flexes the trunk and increases intraabdominal pressure, worsening reflux. A foam wedge elevates the entire upper body from the hips. Correct elevation is 30–45°.
-
Omeprazole + clopidogrel = drug interaction: Both compete for CYP2C19. The preferred PPIs for patients on clopidogrel are lansoprazole, pantoprazole, or rabeprazole. Expect this in a cardiac patient scenario with GERD.
-
H. pylori testing must precede PPI initiation: PPIs suppress H. pylori and reduce urea breath test sensitivity. Order the test first, or hold the PPI for 2 weeks before testing.
-
Gas-bloat syndrome is expected after Nissen fundoplication: The wrap prevents belching; patients will feel distended and may have difficulty vomiting. Treat this as a predictable post-op finding to educate about preoperatively, rather than a complication requiring intervention.
-
Dysphagia after fundoplication: Short-term dysphagia is expected (perioperative edema). Dysphagia persisting beyond 3 months is pathological and requires imaging (barium swallow or EGD to assess wrap integrity).
-
Barrett’s esophagus = metaplasia, not dysplasia: Barrett’s is intestinal metaplasia (a change in cell type). Dysplasia (abnormal cell growth with malignant potential) is a separate finding that can develop within Barrett’s. Know the difference.
-
LINX device restricts MRI: LINX is MR Conditional, with current devices labeled up to 1.5 Tesla. Scanning outside those labeled conditions risks patient injury and device demagnetization. Always document LINX implants and the device model in device reconciliation.
-
LPR presents without classic heartburn: Up to 40% of LPR patients have no pyrosis. Hoarseness, globus, and chronic throat clearing in a patient who denies “heartburn” should still prompt GERD/LPR workup – particularly if they are a teacher, singer, or have unexplained laryngitis.
Related resources
- Peptic ulcer disease nursing reference – H. pylori pathophysiology, eradication regimens, and gastric vs. duodenal ulcer comparison
- GI bleed nursing reference – Esophageal erosions, varices, and priority hemorrhage interventions
- Pancreatitis nursing reference – Concurrent GI assessment and shared monitoring priorities
- Nursing lab values cheat sheet – Electrolytes including magnesium (relevant for long-term PPI monitoring)
- Drug classifications nursing reference – PPI and H2 blocker pharmacology in context
References
- Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27–56. doi:10.14309/ajg.0000000000001538
- Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920. doi:10.1111/j.1572-0241.2006.00630.x
- National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. NICE Clinical Guideline CG184. London: NICE; 2014.
- Lundell LR, Miettinen P, Myrvold HE, et al.; Nordic GORD Study Group. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg. 2001;192(2):172–179. doi:10.1016/S1072-7515(00)00797-3
- Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett’s esophagus: an updated ACG guideline. Am J Gastroenterol. 2022;117(4):559–587. doi:10.14309/ajg.0000000000001680
- Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209–1217. doi:10.1001/jama.2014.2511
- Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–944. doi:10.1001/jama.2009.261
- Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):267–276. doi:10.1053/j.gastro.2017.07.045
- Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710–717. doi:10.1136/gut.2004.051821
- Yadlapati R, Gyawali CP, Pandolfino JE; CGIT GERD Consensus Conference Participants. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: expert review. Clin Gastroenterol Hepatol. 2022;20(5):984–994. doi:10.1016/j.cgh.2022.01.025
- El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880. doi:10.1136/gutjnl-2012-304269
- Galmiche JP, Hatlebakk J, Attwood S, et al.; LOTUS Trial Collaborators. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011;305(19):1969–1977. doi:10.1001/jama.2011.626
- Kellerman R, Kintanar T. Gastroesophageal reflux disease. Prim Care. 2017;44(4):561–573. doi:10.1016/j.pop.2017.07.001
- Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383–1391. doi:10.1053/j.gastro.2008.08.045
- Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the Reflux Symptom Index (RSI). J Voice. 2002;16(2):274–277. doi:10.1016/S0892-1997(02)00097-8
- Ganz RA, Peters JH, Horgan S, et al. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med. 2013;368(8):719–727. doi:10.1056/NEJMoa1205544
- Brown J, Matz O, Sutton AE, Shermetaro C. Laryngopharyngeal reflux. In: StatPearls. Treasure Island, FL: StatPearls Publishing; updated November 29, 2025. NCBI Bookshelf ID: NBK519548.
- Potter PA, Perry AG, Stockert P, Hall A. Fundamentals of Nursing. 10th ed. St. Louis, MO: Elsevier; 2021. Chapter 45: Bowel elimination and GI assessment.